US › Healthcare

FibroBiologics, Inc. Common Stock (FBLG)

US · Healthcare · Biotechnology

$0.82+3.98%
Last close · 2026-08-04

Latest quarter · ended 2026-03-31

Revenue
$0
Net profit
$-5.0M
Profit YoY
-0.7%
EPS
$-1.33
EPS estimate
$-1.35

EPS came in at -1.33 against a street estimate of -1.35 — a beat of 1.8%.

Key statistics

Market cap
$4.1M
Forward P/E
0.0
P/B
1.64
Book value
$0.76
EPS (TTM)
$-5.10
52-week high
$12.80
52-week low
$0.62
50-day MA
$0.88
200-day MA
$4.06
Beta
1.22

Analyst view

Analysts rate FibroBiologics, Inc. Common Stock a buy (3 buy, 0 hold, 0 sell out of 3) with an average price target of $13.50.

Shareholding

Insiders
10.81%
Institutions
10.72%

Largest institutional holders

FundStake
Vanguard Capital Management, LLC1.28%
Vanguard Group Inc1.15%
Fund Evaluation Group, LLC0.98%
Geode Capital Management, LLC0.56%
BlackRock Inc0.47%
Renaissance Technologies Corp0.30%
Vanguard Fiduciary Trust Co0.12%
UBS Group AG0.11%

See the full picture

Technicals, trade setups with a published hit rate, $AI analysis and earnings-call summaries for FibroBiologics, Inc. Common Stock — free to start.

Google PlayApp Store

Other Healthcare companies

Eli Lilly and CompanyJohnson & JohnsonAbbVie IncUnitedHealth Group IncorporatedMerck & Company IncNovartis AG ADRAstraZeneca PLCThermo Fisher Scientific IncNovo Nordisk A/SAmgen IncAbbott LaboratoriesGilead Sciences Inc

Data updated 2026-08-05.